Valuation: Pfizer Limited

Market Cap 183B 1.91B 1.66B 1.57B 1.43B 2.67B 2.68B 18.82B 7.26B 93.09B 7.17B 7.01B 300B P/E 2027 *
22.6x
P/E 2028 * 19.6x
Enterprise Value 183B 1.91B 1.66B 1.57B 1.43B 2.67B 2.68B 18.82B 7.26B 93.09B 7.17B 7.01B 300B EV / Sales 2027 *
6.91x
EV / Sales 2028 * 6.33x
Free-Float
33.05%
Yield 2027 *
1.56%
Yield 2028 * 1.7%
1 day-0.31%
1 week-2.27%
Current month-14.56%
1 month-17.12%
3 months-10.93%
6 months-15.30%
Current year-19.75%
1 week 3,955.5
Extreme 3955.5
4,091.1
1 month 3,955.5
Extreme 3955.5
5,030
Current year 3,955.5
Extreme 3955.5
5,257
1 year 3,955.5
Extreme 3955.5
5,578.5
3 years 3,701
Extreme 3701
6,451.15
5 years 3,408
Extreme 3408
6,451.15
10 years 1,642
Extreme 1642
6,451.15
Manager TitleAgeSince
Chief Executive Officer 55 2023-04-02
Director of Finance/CFO - 2024-02-25
Chief Tech/Sci/R&D Officer - 2023-03-31
Director TitleAgeSince
Chairman 73 1999-12-06
Director/Board Member 63 2019-03-07
Director/Board Member 55 2023-04-02
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-2.27%-23.07%+2.49% 1.92B
-0.83%+2.45%+49.83%+100.09% 1,027B
0.00%+1.55%+54.86%+66.00% 651B
-0.01%+2.66%+18.90%+71.46% 467B
-1.22%+3.66%+36.44%+38.32% 350B
-0.79%+2.73%+19.03%+25.08% 268B
+0.58%+6.76%+11.13%+16.52% 257B
+0.78%+1.44%+38.78%+45.46% 205B
+0.79%+1.84%-28.27%-56.71% 190B
-0.12%+4.70%+32.43%+98.98% 187B
Average -0.15%+2.04%+21.01%+40.77% 360.4B
Weighted average by Cap. -0.31%+2.62%+34.70%+61.21%

Financials

2027 *2028 *
Net sales 26.5B 276M 241M 227M 206M 387M 388M 2.72B 1.05B 13.47B 1.04B 1.01B 43.35B 28.92B 301M 263M 248M 225M 422M 424M 2.97B 1.15B 14.7B 1.13B 1.11B 47.3B
Net income 8.09B 84.32M 73.52M 69.42M 63.04M 118M 119M 832M 321M 4.11B 317M 310M 13.24B 9.36B 97.58M 85.09M 80.35M 72.96M 137M 137M 962M 371M 4.76B 367M 358M 15.32B
Net Debt - -
Logo Pfizer Limited
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Employees
1,244
Date Price Change Volume
26-09-18 4,002.40 -0.31% 42,189
26-09-17 ₹4,014.80 +0.01% 20,865
26-09-16 ₹4,014.40 -0.67% 37,281
26-09-15 ₹4,041.60 -0.46% 36,144
26-09-11 ₹4,060.20 -0.86% 138,685

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PFIZER Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!